UCFA
SUPN icon

United Capital Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

United Capital Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-51,030
Closed -$2.34M – 1360
2018
Q1 		$2.34M Buy
51,030
+535
+1% +$22.3K 0.02% 550
2017
Q4 		$2.01M Buy
50,495
+3,443
+7% +$136K 0.02% 583
2017
Q3 		$1.88M Buy
47,052
+477
+1% +$20.6K 0.02% 590
2017
Q2 		$2.01M Buy
+46,575
New +$1.66M 0.02% 575

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

United Capital Financial Advisors's SUPN Position: Q2 2018 in Review

United Capital Financial Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2018, closing a stake of 51,030 shares — an estimated $2.34M sold.

United Capital Financial Advisors first reported a position in SUPN in Q2 2017 and held it in 4 quarters. The position peaked at $2.34M in Q1 2018. 320 funds tracked by Wall St. Rank hold SUPN as of Q2 2018.

  • United Capital Financial Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • United Capital Financial Advisors sold 51,030 Supernus Pharmaceuticals shares in Q2 2018, an estimated $2.34M.
  • United Capital Financial Advisors first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • United Capital Financial Advisors's Supernus Pharmaceuticals position peaked at $2.34M in Q1 2018.
  • 320 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2018.

Based on United Capital Financial Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.